208 related articles for article (PubMed ID: 23296123)
21. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
22. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
Decrausaz L; Domingos-Pereira S; Duc M; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
Int J Cancer; 2011 Aug; 129(3):762-72. PubMed ID: 21384340
[TBL] [Abstract][Full Text] [Related]
23. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.
Bissa M; Illiano E; Pacchioni S; Paolini F; Zanotto C; De Giuli Morghen C; Massa S; Franconi R; Radaelli A; Venuti A
J Transl Med; 2015 Mar; 13():80. PubMed ID: 25763880
[TBL] [Abstract][Full Text] [Related]
24. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
[TBL] [Abstract][Full Text] [Related]
25. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
26. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
Wieking BG; Vermeer DW; Spanos WC; Lee KM; Vermeer P; Lee WT; Xu Y; Gabitzsch ES; Balcaitis S; Balint JP; Jones FR; Lee JH
Cancer Gene Ther; 2012 Oct; 19(10):667-74. PubMed ID: 22918471
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
28. HPV-positive murine oral squamous cell carcinoma: development and characterization of a new mouse tumor model for immunological studies.
Modic Z; Cemazar M; Markelc B; Cör A; Sersa G; Kranjc Brezar S; Jesenko T
J Transl Med; 2023 Jun; 21(1):376. PubMed ID: 37296466
[TBL] [Abstract][Full Text] [Related]
29. Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.
Zottnick S; Voß AL; Riemer AB
Front Immunol; 2020; 11():1750. PubMed ID: 32922389
[TBL] [Abstract][Full Text] [Related]
30. Customized Viral Immunotherapy for HPV-Associated Cancer.
Atherton MJ; Stephenson KB; Pol J; Wang F; Lefebvre C; Stojdl DF; Nikota JK; Dvorkin-Gheva A; Nguyen A; Chen L; Johnson-Obaseki S; Villeneuve PJ; Diallo JS; Dimitroulakos J; Wan Y; Lichty BD
Cancer Immunol Res; 2017 Oct; 5(10):847-859. PubMed ID: 28912369
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Vaccines Against Human Papilloma Viruses: Achievements and Prospects.
Vonsky MS; Runov AL; Gordeychuk IV; Isaguliants MG
Biochemistry (Mosc); 2019 Jul; 84(7):800-816. PubMed ID: 31509730
[TBL] [Abstract][Full Text] [Related]
32. A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers.
Decrausaz L; Gonçalves AR; Domingos-Pereira S; Pythoud C; Stehle JC; Schiller J; Jichlinski P; Nardelli-Haefliger D
Int J Cancer; 2011 May; 128(9):2105-13. PubMed ID: 20635385
[TBL] [Abstract][Full Text] [Related]
33. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
34. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
35. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.
Braakhuis BJ; Snijders PJ; Keune WJ; Meijer CJ; Ruijter-Schippers HJ; Leemans CR; Brakenhoff RH
J Natl Cancer Inst; 2004 Jul; 96(13):998-1006. PubMed ID: 15240783
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
Hung CF; Ma B; Monie A; Tsen SW; Wu TC
Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
[TBL] [Abstract][Full Text] [Related]
38. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
39. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
40. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]